ORION-9

#AHA19

AMERICAN COLLEGE of CARDIOLOGY

Trial Description: Patients at HeFH on maximally tolerated statin were randomized to either inclisiran 300 mg or matching placebo. They were followed for 510 days.



RESULTS

- Primary endpoint, % LDL-C change, for inclisiran vs. placebo, -41% vs. 8% ($p < 0.0001$); absolute difference: 70.6 mg/dl
- Protocol-defined event: 13.7% vs. 0.4% ($p < 0.05$)
- All-cause mortality: 0.4% vs. 0.4%

CONCLUSIONS

- Inclisiran is superior to placebo in reducing LDL-C among patients with HeFH who are already on statins and ezetimibe
- CV outcomes trials are awaited – magnitude of benefit in LDL-C seems to be similar to what was observed with PCSK9 inhibitors

Presented by Dr. Frederick J. Raal at AHA 2019